Kirven J, Beddow D, Patel L, et al. - Early-onset neonatal Group B streptococcus (GBS) disease is identified as a common cause of infectious morbidity and mortality in the first week of life. Vertical transmission during delivery results in the spread of this infection from GBS positive mothers to neonates, which leads to serious illness for newborns. The incidence of early-onset neonatal GBS disease decreases by 80% with providing intrapartum prophylactic antibiotics. Either vancomycin or clindamycin are provided alternatively to patients labeled with a penicillin allergy (PcnA) but effectiveness is controversial. Researchers herein investigated the impact of a reported PcnA label vs no PcnA label on inpatient maternal and neonatal outcomes. They obtained retrospective data for hospitalized patients who were GBS positive, pregnant at time of admission, ≥ 18 years of age, received antibiotic prophylaxis for GBS, were labeled as PcnA or non-PcnA, and completed a vaginal delivery. Per outcomes, a PcnA label in hospitalized obstetric patients was linked with a shorter maternal course of antibiotic treatment and a longer neonatal LOS.